SQZ Biotechnologies Gross Margin 2020-2022 | SQZ

Current and historical gross margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current gross profit margin for SQZ Biotechnologies as of March 31, 2022 is %.
SQZ Biotechnologies Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.03B $0.03B 100.00%
2021-12-31 $0.03B $0.03B 100.00%
2021-09-30 $0.02B $0.02B 100.00%
2021-06-30 $0.02B $0.02B 100.00%
2021-03-31 $0.02B $0.02B 100.00%
2020-12-31 $0.02B $0.02B 100.00%
2020-06-30 $0.02B $0.02B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.092B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00